Citations for
1HOGA1, PHXL3
The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3.
Williams EL, Bockenhauer D, van't Hoff WG, Johri N, Laing C, Sinha MD, Unwin R, Viljoen A, Rumsby G.
Nephrol Dial Transplant 27(8):3191-5. doi: 10.1093/ndt/gfs039. Epub 2012 Mar 5. 2012
2HOGA1, PHXL3
4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibition.
Riedel TJ, Knight J, Murray MS, Milliner DS, Holmes RP, Lowther WT.
Biochim Biophys Acta 1822(10):1544-52. doi: 10.1016/j.bbadis.2012.06.014. Epub 2012 Jul 5. 2012
3HOGA1, PHXL3
Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis.
Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS.
Clin J Am Soc Nephrol 6(9):2289-95. doi: 10.2215/CJN.02760311. 2011
4DHPDSL, HOGA1, PHXL3
Mutations in DHDPSL are responsible for primary hyperoxaluria type III.
Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y.
Am J Hum Genet 87(3):392-9.PMID: 20797690 2010
5AGAP10, AGAP6, AGAP7, AGAP8, AKR1CL1, ALDH18A1, ANXA8L1, BTBD16, C10orf103, C10orf108, C10orf111, C10orf113, C10orf114, C10orf115, C10orf120, C10orf122, C10orf25, C10orf26, C10orf30, C10orf32, C10orf35, C10orf47, C10orf55, C10orf67, C10orf71, CACUL1, CALHM1, CH25H, EBF3, FAM22D, FAM23A, FAM23B, FAM24A, FAM25A, FAM25B, FAM25C, FAM25D, FAM25E, FAM25G, FAM25HP, FZD8, GPAM, HECTD2, HOGA1, PDE6C, SYNPO2L, TET1, UTF1, VAX1, XPNPEP1, YME1L1, ZCCHC24, ZNF511
The DNA sequence and comparative analysis of human chromosome 10.
Deloukas P, Earthrowl ME, Grafham DV, Rubenfield M, French L, Steward CA, Sims SK, Jones MC, Searle S, Scott C, Howe K, Hunt SE, Andrews TD, Gilbert JG, Swarbreck D, Ashurst JL, Taylor A, Battles J, Bird CP, Ainscough R, Almeida JP, Ashwell RI, Ambrose KD, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Bates K, Beasley H, Bray-Allen S, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Cahill P, Camire D, Carter NP, Chapman JC, Clark SY, Clarke G, Clee CM, Clegg S, Corby N, Coulson A, Dhami P, Dutta I, Dunn M, Faulkner L, Frankish A, Frankland JA, Garner P, Garnett J, Gribble S, Griffiths C, Grocock R, Gustafson E, Hammond S, Harley JL, Hart E, Heath PD, Ho TP, Hopkins B, Horne J, Howden PJ, Huckle E, Hynds C, Johnson C, Johnson D, Kana A, Kay M, Kimberley AM, Kershaw JK, Kokkinaki M, Laird GK, Lawlor S, Lee HM, Leongamornlert DA, Laird G, Lloyd C, Lloyd DM, Loveland J, Lovell J, McLaren S, McLay KE, McMurray A, Mashreghi-Mohammadi M, Matthews L, Milne S, Nickerson T, Nguyen M, Overton-Larty E, Palmer SA, Pearce AV, Peck AI, Pelan S, Phillimore B, Porter K, Rice CM, Rogosin A, Ross MT, Sarafidou T, Sehra HK, Shownkeen R, Skuce CD, Smith M, Standring L, Sycamore N, Tester J, Thorpe A, Torcasso W, Tracey A, Tromans A, Tsolas J, Wall M, Walsh J, Wang H, Weinstock K, West AP, Willey DL, Whitehead SL, Wilming L, Wray PW, Young L, Chen Y, Lovering RC, Moschonas NK, Siebert R, Fechtel K, Bentley D, Durbin R, Hubbard T, Doucette-Stamm L, Beck S, Smith DR, Rogers J.
Nature 429(6990):375-81. 2004